Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A phase 3 trial shows satralizumab cut relapse risk by 68% in patients with MOGAD, a rare demyelinating disease that can cause serious neurological and visual damage. Nearly 9 in 10 patients on the drug remained relapse-free at 48 weeks. The FDA is now reviewing satralizumab as a potential first-ever approved therapy for MOGAD, with a decision expected by January 2027.
A rare demyelinating disease may finally have a targeted treatment on the horizon. The phase 3 METEOROID trial found that satralizumab (Enspryng; Genentech) significantly reduced relapse risk in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) — a condition that can cause serious neurological and visual disability and currently has no FDA-approved disease-modifying therapies.
The double-blind, placebo-controlled study enrolled 132 patients aged 12 and older. Satralizumab, already approved for neuromyelitis optica spectrum disorder (NMOSD), was administered subcutaneously with or without additional immunosuppressive therapy. Results were presented at the 2026 Child Neurology Society Annual Meeting in Montreal.
By the Numbers:
Why it matters: Clinicians currently rely on off-label immunosuppressants like rituximab and azathioprine to manage MOGAD. With the FDA granting priority review and a decision expected by January 10, 2027, satralizumab could become the first approved therapy specifically for this condition — a major step forward for patients.
